国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
23期
3534-3537
,共4页
张盛奇%林丽芳%郑泓斌%方玫玫
張盛奇%林麗芳%鄭泓斌%方玫玫
장성기%림려방%정홍빈%방매매
褪黑素%化疗%晚期食管癌
褪黑素%化療%晚期食管癌
퇴흑소%화료%만기식관암
Melatonin%Chemotherapy%Advanced esophageal cancer
目的 探讨褪黑素联合化疗对晚期食管癌患者的影响,为临床治疗提供依据.方法 选择2011年6月至2013年5月我院收治的40例初治晚期食管癌患者作为研究对象(观察组),另外选择同期收治的初治晚期食道癌患者40例作为对照组.观察组采用褪黑素联合化疗的方式进行治疗,对照组仅进行化疗,不使用褪黑素.评价两组患者的临床疗效、Karnofsky行为状况评分、外周血中T淋巴细胞亚群的指标.结果 观察组完全缓解10例,占25.00％,部分缓解17例,占42.50％,总有效率为67.5％;对照组完全缓解9例,占22.50％,部分缓解17例,占42.50％,总有效率为65.0％;两组比较差异无统计学意义(P＞0.05).观察组Karnofsky行为状况评分改善15例,占37.50％,稳定21例,占52.50％,恶化4例,占10.00％,与对照组比较差异有统计学意义(P＜0.05).观察组CD3+和CD4+水平明显高于对照组,差异有统计学意义(P＜0.05);两组CD8+水平比较差异无统计学意义(P＞0.05);观察组CD++/CD8+比值明显高于对照组,差异有统计学意义(P＜0.05).结论 褪黑素联合化疗对晚期食管癌患者临床疗效影响不大,但是能够提高免疫力及降低不良反应,在肿瘤辅助治疗中具有增强疗效、降低毒性等作用.
目的 探討褪黑素聯閤化療對晚期食管癌患者的影響,為臨床治療提供依據.方法 選擇2011年6月至2013年5月我院收治的40例初治晚期食管癌患者作為研究對象(觀察組),另外選擇同期收治的初治晚期食道癌患者40例作為對照組.觀察組採用褪黑素聯閤化療的方式進行治療,對照組僅進行化療,不使用褪黑素.評價兩組患者的臨床療效、Karnofsky行為狀況評分、外週血中T淋巴細胞亞群的指標.結果 觀察組完全緩解10例,佔25.00％,部分緩解17例,佔42.50％,總有效率為67.5％;對照組完全緩解9例,佔22.50％,部分緩解17例,佔42.50％,總有效率為65.0％;兩組比較差異無統計學意義(P＞0.05).觀察組Karnofsky行為狀況評分改善15例,佔37.50％,穩定21例,佔52.50％,噁化4例,佔10.00％,與對照組比較差異有統計學意義(P＜0.05).觀察組CD3+和CD4+水平明顯高于對照組,差異有統計學意義(P＜0.05);兩組CD8+水平比較差異無統計學意義(P＞0.05);觀察組CD++/CD8+比值明顯高于對照組,差異有統計學意義(P＜0.05).結論 褪黑素聯閤化療對晚期食管癌患者臨床療效影響不大,但是能夠提高免疫力及降低不良反應,在腫瘤輔助治療中具有增彊療效、降低毒性等作用.
목적 탐토퇴흑소연합화료대만기식관암환자적영향,위림상치료제공의거.방법 선택2011년6월지2013년5월아원수치적40례초치만기식관암환자작위연구대상(관찰조),령외선택동기수치적초치만기식도암환자40례작위대조조.관찰조채용퇴흑소연합화료적방식진행치료,대조조부진행화료,불사용퇴흑소.평개량조환자적림상료효、Karnofsky행위상황평분、외주혈중T림파세포아군적지표.결과 관찰조완전완해10례,점25.00％,부분완해17례,점42.50％,총유효솔위67.5％;대조조완전완해9례,점22.50％,부분완해17례,점42.50％,총유효솔위65.0％;량조비교차이무통계학의의(P＞0.05).관찰조Karnofsky행위상황평분개선15례,점37.50％,은정21례,점52.50％,악화4례,점10.00％,여대조조비교차이유통계학의의(P＜0.05).관찰조CD3+화CD4+수평명현고우대조조,차이유통계학의의(P＜0.05);량조CD8+수평비교차이무통계학의의(P＞0.05);관찰조CD++/CD8+비치명현고우대조조,차이유통계학의의(P＜0.05).결론 퇴흑소연합화료대만기식관암환자림상료효영향불대,단시능구제고면역력급강저불량반응,재종류보조치료중구유증강료효、강저독성등작용.
Objective To provide some evidences for treating advanced esophageal cancer exploring the effect of melatonin in combination with chemotherapy on patients with advanced esophageal cancer.Methods 40 patients with advanced esophageal cancer undergoing initial treatment were selected from our hospital from June,2011 to May,2013 as research objects (observation group).Another 40 patients with advanced esophageal cancer undergoing initial treatment were enrolled into the control group.The observation group was treated with melatonin and chemotherapy,while the control group was treated with only chemotherapy.The clinical efficacies,Karnofsky behavior scores,and the indicators of T lymphocyte subsets in peripheral blood of both groups were evaluated.Results 10 cases (25.00％) got complete remission and 17 cases (42.50％) got partial remission in the observation group with a total effective rate of 67.50％.9 cases (22.50％) got complete remission and 17 cases (42.50％) got partial remission in the control group with a total effective rate of 65.00％.There was no statistical difference in total effective rate between the two groups (P ＞ 0.05).15 cases (37.50％) got better,21 cases (52.50％) were stable,and 4 cases (10.00％) deteriorated in Karnofsky behavior score in the observation group,which were better than that in the control group,with statistical differences (P ＜ 0.05).CD3+ and CD4+ levels were significantly higher in the observation group than in the control group,with statistical differences (P ＜ 0.05).There was no statistical difference in CD8+level between the two groups (P＞0.05).CD4+/CD8+ ratio was significantly higher in the observation group than in the control group,with a statistical difference (P ＜ 0.05).Conclusions Melatonin in combination with chemotherapy has little influence on the clinical curative effect of patients with advanced esophageal cancer,but can improve the patients' immunity and reduce adverse reactions,enhance the efficacy in tumor auxiliary treatment,and reduce toxicity effect.
